EKF Diagnostics Holdings plc

Equities

EKF

GB0031509804

Advanced Medical Equipment & Technology

Market Closed - London S.E. Other stock markets 11:35:26 2024-06-07 am EDT			5-day change	1st Jan Change
29.4 ^GBX	-1.18%		-9.40%	-7.11%

May. 15	Future Metals celebrates state government grant	AN
May. 14	EKF Diagnostics Holdings Says Q1 Adj EBITDA Shows About 20% Improvement	RE

EKF Diagnostics : Investor Presentations

June 07, 2021 at 06:05 am EDT

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed point-of-care business, announces that Julian Baines and Mike Salter (who will become Chief Executive Officer on 1 October 2021) will be presenting to institutional investors this week following the recent AGM statement which set out the Company's strategy for growth through to 2024.

No new price sensitive information will be disclosed, and a PDF of the presentation will be made available on the Company's website: https://www.ekfdiagnostics.com/documents-reports.html

Enquiries:

EKF Diagnostics Holdings plc
Christopher Mills, Non-Executive Chairman
Julian Baines, CEO
Richard Evans, FD and COO

www.ekfdiagnostics.com
Tel: 00 44 29 2071 0570

N+1 Singer (Nomad & Broker)

Aubrey Powell / George Tzimas (Corporate Finance)

Tom Salvesen (Corporate Broking)

Tel: 020 7496 3000

Walbrook PR Limited
Paul McManus
Lianne Cawthorne

Tel: 020 7933 8780 or
Mob: 07980 541 893 / 07584 391 303

Attachments

Original document
Permalink

Disclaimer

EKF Diagnostics Holdings plc published this content on 07 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 June 2021 10:04:00 UTC.

Latest news about EKF Diagnostics Holdings plc

Future Metals celebrates state government grant	May. 15	AN
EKF Diagnostics Holdings Says Q1 Adj EBITDA Shows About 20% Improvement	May. 14	RE
Onward Opportunities' small-cap strategy yields solid results in 2023	Apr. 11	AN
EKF Diagnostics says prospects "promising" but pauses dividends	Mar. 20	AN
EKF Diagnostics Holdings plc Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
EKF Diagnostics reports trading in line with expectations	Jan. 29	AN
EKF Diagnostics Holdings plc Provides Earnings Guidance for the Full Year 2023	Jan. 29	CI
EKF Diagnostics Holdings plc Announces the Official Opening of its New State-Of-The-Art Life Sciences Manufacturing Site in South Bend, Indiana, United States	23-10-26	CI
EARNINGS: FireAngel Safety interim loss widens amid ongoing headwinds	23-09-26	AN
Earnings Flash (EKF.L) EKF DIAGNOSTICS HOLDINGS Reports H1 Revenue GBP26.9M	23-09-26	MT
EKF Diagnostics Holdings plc Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-26	CI
FTSE 100 Closes Tuesday Up 0.41% as Oil-Price Rises Benefit the Index	23-09-12	DJ
EKF Diagnostics hires CFO from Trellus Health, latter names successor	23-09-12	AN
FTSE 100 Rises, Led by AB Foods; Smurfit Kappa Slides	23-09-12	DJ
Trellus Health's Interim Finance Head Takes Full-time CFO Role at EKF Diagnostics	23-09-12	MT
EKF Diagnostics Holdings plc Provides Financial Guidance for the Year Ending 31 December 2023	23-09-12	CI
EKF Diagnostics Holdings plc Appoints Stephen Young as Chief Financial Officer	23-09-12	CI
Revolution Bars reports good progress from Peach Pubs	23-07-26	AN
FTSE 100 Closes Down 0.2% as Miners Offset Ocado, -2-	23-07-26	DJ
FTSE 100 Closes Up 0.5% as Sage Group Shines	23-06-28	DJ
SONIA Illiquidity Could Explain Disconnect in BOE Peak Rate Pricing	23-06-28	DJ
EKF Diagnostics says CFO Davies resigns to pursue other opportunities	23-06-28	AN
EKF Diagnostics CFO Plans Exit; Successor to Assume Role in Q4	23-06-28	MT
Marc Davies to Step Down as Chief Financial Officer of EKF Diagnostics Holdings plc	23-06-28	CI
EKF Diagnostics announces enzyme fermenter progress	23-06-20	AN

Chart EKF Diagnostics Holdings plc

Duration

Period

More charts

Company Profile

EKF Diagnostics Holdings plc is a United Kingdom-based diagnostics company. The Company is engaged in point-of-care testing, central laboratory tests, enzyme manufacturing and the provision of contract manufacturing services to the healthcare industry. Its principal activity is the development, manufacture and supply of products into the in-vitro diagnostics marketplace. Its point of care analyzers is designed for use within doctors' surgeries, clinics, blood banks and hospital and private laboratories to provide results. Its life sciences specialize in producing enzymes and contracted custom products for use in medical diagnostics, pharmaceuticals and industry. Its life science facilities are based in two locations in Indiana, United States. Its central laboratory division manufactures a spectrum of reagents for use in hospital laboratories. Its contract manufacturing business provides specialized services to the diagnostics and healthcare industries for the production of custom kits.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-09-09 - Q2 2024 Earnings Release (Projected)

More about the company